Table 1. Clinical Response to the Fungal Meningitis Epidemic^a.

Reference	Inferences
3	CDC recommends voriconazole as an effective drug to treat infections caused by the predominant pathogen, Exserohilum rostratum.
5,6	Pharmacies adapted to the emerging clinical evidence and evolving treatment recommendations from the CDC; high-dose dual therapy with voriconazole and liposomal amphotericin B was revised to monotherapy with voriconazole for patients without serious illness.
7	172 patients were exposed to contaminated epidural steroid injections and presented for care in a Virginia hospital; most of these patients were diagnosed with meningitis and most patients improved their health with voriconazole therapy.
8	Fungal meningitis treatment familiarity at Saint Joseph Mercy hospital led to a centralized approach of consistent care delivery and care management for the infected patients in Michigan.
9	The novelty of the fungal meningitis infections led to long-term uncertainty about their clinical progression, and patients were closely monitored for optimal drug intake and any adverse effects.
10	Patients were recommended to continue oral voriconazole treatment at home, following hospital release for months based on the follow-up tests and disease progression.
10	Magnetic resonance imaging screenings assisted in identifying patients for initiating early medical or surgical treatment.
11	Voriconazole drug therapy was prescribed for all 153 patients with probable or confirmed spinal or paraspinal infection at the Saint Joseph Mercy hospital in Michigan, with liposomal amphotericin B also prescribed for 75% of these patients.
12	There is no consensus in management of exposed asymptomatic patients and symptomatic patients with negative lab tests, thereby leading to variations in clinical treatment of exposed patients, both symptomatic and asymptomatic.

^aAbbreviation: CDC, Centers for Disease Control and Prevention.